JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Insulet (NASDAQ:PODD) Stock

Insulet (NASDAQ:PODD) had its price objective hoisted by research analysts at JPMorgan Chase & Co. from $152.00 to $170.00 in a research report issued on Thursday, Benzinga reports. The brokerage currently has a “neutral” rating on the medical instruments supplier’s stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 16.03% from the stock’s previous close.

A number of other research firms also recently commented on PODD. Leerink Partners boosted their target price on shares of Insulet from $143.00 to $167.00 and gave the stock a “market perform” rating in a report on Thursday. Canaccord Genuity Group decreased their price target on shares of Insulet from $249.00 to $179.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Oppenheimer cut Insulet from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 5th. Wall Street Zen downgraded Insulet from a “buy” rating to a “hold” rating in a research report on Saturday, October 24th. Finally, Sanford C. Bernstein raised their price objective on Insulet from $175.00 to $200.00 and gave the stock an “outperform” rating in a research note on Thursday. Twelve analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $185.38.

Insulet Price Performance

PODD stock traded down $9.61 during trading hours on Thursday, hitting $146.51. 1,567,721 shares of the stock traded hands, compared to its average volume of 1,380,594. The stock has a 50-day simple moving average of $141.97 and a 200 day simple moving average of $176.65. Insulet has a one year low of $126.40 and a one year high of $354.88. The company has a market cap of $10.16 billion, a P/E ratio of 23.86, a P/E/G ratio of 1.21 and a beta of 1.06. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 EPS for the quarter, topping the consensus estimate of $1.59 by $0.40. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The firm had revenue of $842.00 million for the quarter, compared to analysts’ expectations of $832.63 million. During the same period in the previous year, the business earned $1.24 earnings per share. Insulet’s revenue for the quarter was up 19.2% compared to the same quarter last year. Equities analysts forecast that Insulet will post 6.75 earnings per share for the current year.

Institutional Investors Weigh In On Insulet

Large investors have recently made changes to their positions in the company. Elevation Wealth Partners LLC boosted its stake in Insulet by 115.6% in the 3rd quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 104 shares during the period. Activest Wealth Management grew its holdings in shares of Insulet by 186.3% during the 3rd quarter. Activest Wealth Management now owns 229 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 149 shares in the last quarter. WPG Advisers LLC grew its holdings in shares of Insulet by 169.3% during the 3rd quarter. WPG Advisers LLC now owns 272 shares of the medical instruments supplier’s stock valued at $35,000 after acquiring an additional 171 shares in the last quarter. Covestor Ltd increased its stake in shares of Insulet by 103.9% in the third quarter. Covestor Ltd now owns 310 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 158 shares during the last quarter. Finally, Jacobi Capital Management LLC acquired a new position in shares of Insulet in the third quarter worth $40,000.

Key Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Several firms raised targets and maintained bullish ratings: RBC lifted its target to $180 and kept an Outperform rating, Bernstein raised its target to $200 and kept Outperform, and Canaccord reiterated Buy with a $179 target. RBC target update Canaccord rating update
• Positive Sentiment: Other analysts also raised targets, while commentary described Insulet as potentially undervalued and highlighted its $1 billion buyback. Recent quarterly results provide support: the company beat earnings and revenue estimates, with revenue up 19.2% year over year, according to the supplied company data. Valuation and buyback article
• Neutral Sentiment: UBS, JPMorgan, Citi, Barclays, Wells Fargo and Leerink all increased their price targets, generally retaining Neutral, Equal Weight or Market Perform ratings. The higher targets are supportive, but the largely unchanged ratings suggest analysts see risks as well as recovery potential.
• Negative Sentiment: Analyst discussion flagged a more conservative 2027 outlook and competition, tempering optimism about Insulet’s growth. Coverage characterized the outlook as moderate despite international strength and an innovation pipeline. RBC outlook article Q3 growth analysis

Insulet Company Profile

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.